OAM
LFCR icon

Oppenheimer Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Oppenheimer Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,001
Closed -$228K – 1164
2024
Q1 		$228K Buy
43,001
+19,094
+80% +$137K ﹤0.01% 1021
2023
Q4 		$148K Sell
23,907
-9,625
-29% -$66.8K ﹤0.01% 1122
2023
Q3 		$253K Sell
33,532
-31,443
-48% -$287K ﹤0.01% 999
2023
Q2 		$628K Buy
64,975
+6,975
+12% +$42.6K 0.01% 803
2023
Q1 		$219K Sell
58,000
-19,221
-25% -$107K ﹤0.01% 1032
2022
Q4 		$500K Sell
77,221
-4,690
-6% -$38.7K 0.01% 860
2022
Q3 		$728K Sell
81,911
-704
-0.9% -$7.16K 0.01% 748
2022
Q2 		$824K Buy
82,615
+21,498
+35% +$213K 0.01% 729
2022
Q1 		$708K Buy
61,117
+6,638
+12% +$73.9K 0.01% 837
2021
Q4 		$605K Buy
54,479
+675
+1% +$6.55K 0.01% 914
2021
Q3 		$496K Buy
53,804
+3,423
+7% +$37.2K 0.01% 938
2021
Q2 		$567K Buy
50,381
+3,598
+8% +$41.5K 0.01% 915
2021
Q1 		$496K Buy
46,783
+22,207
+90% +$250K 0.01% 915
2020
Q4 		$267K Buy
24,576
+12,305
+100% +$127K ﹤0.01% 1012
2020
Q3 		$119K Buy
+12,271
New +$117K ﹤0.01% 1053

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Oppenheimer Asset Management's LFCR Position: Q2 2024 in Review

Oppenheimer Asset Management sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 43,001 shares — an estimated $228K sold.

Oppenheimer Asset Management first reported a position in LFCR in Q3 2020 and held it in 15 quarters. The position peaked at $824K in Q2 2022. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

  • Oppenheimer Asset Management reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer Asset Management sold 43,001 Lifecore Biomedical shares in Q2 2024, an estimated $228K.
  • Oppenheimer Asset Management first reported a position in Lifecore Biomedical in Q3 2020 and held it in 15 quarters.
  • Oppenheimer Asset Management's Lifecore Biomedical position peaked at $824K in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Oppenheimer Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.